Persistence Market Research is released new forthcoming report on title "Infectious Diseases Therapeutics Market – Global Industry Analysis and Forecast to 2020".
New York, NY -- (SBWIRE) -- 10/09/2014 -- Globally, major burden on public health is posed by infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, hepatitis C, hepatitis C and influenza. Infectious diseases are the major cause of death in the world. According to World Health Organization (WHO), globally 16% of deaths are resulted due to infectious diseases. Various pathogen microorganisms, such as parasites, virus, bacteria and fungi, cause infectious diseases. Poor sanitation and inadequate personal hygiene causes various infectious diseases. These diseases are transmitted through direct or indirect contact. Anti-infective drugs are used to prevent or destroy the growth of pathogens. Antibacterial, antiviral, antifungal and antiparacitic drugs are some of the anti- infective drugs used for the treatment of infectious diseases.
Request Full Report:
North America dominates the global market for infectious diseases therapeutics due to increasing incidence of infectious diseases and rise in aging population. Asia followed by the Europe are expected to show high growth rates in the next five years in the global infectious diseases therapeutics market. China and India are expected to be the fastest growing infectious diseases therapeutics markets in Asia-Pacific region. Some of the key driving forces for infectious diseases therapeutics market in emerging countries are large pool of patients and rising government funding.
In recent times there is increased use of infectious diseases therapeutics due to increasing incidence of infectious diseases. Increase use of direct acting anti-viral, increase in geriatric population and increasing healthcare expenditure are some of the key factors driving the growth for the global infectious diseases therapeutics market. In addition, increasing healthcare awareness is also fuelling the growth of the global infectious diseases therapeutics market. However, generic erosion is the major factors restraining the growth for the global infectious diseases therapeutics market.
Patent expiration of infectious disease drugs could lead a challenge for the global infectious diseases therapeutics market. Some of the trends for the global infectious diseases therapeutics market are emergence of interferon free regimes and increasing awareness programs. Some of the major companies operating in the global infectious diseases therapeutics market are Merck & Co., Pfizer, Johnson & Johnson, F. Hoffmann-La Roche, GlaxoSmithKline Pharmaceutical, Inc., Auritec Pharmaceuticals, Novartis, Achillion Pharmaceuticals, Isis Pharmaceuticals and Gilead Sciences.
Request Full Toc:
Key points covered in the report:
Report segments the market on the basis of types, application, products, technology, etc (as applicable)
The report covers geographic segmentation
The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020
The report provides company profiles of some of the leading companies operating in the market
The report also provides porters five forces analysis of the market.
About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.